12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Company News  |  Deals

Ambrx, Zhejiang Medicine deal

Ambrx granted Zhejiang rights in China to develop and commercialize Ambrx's ARX788 to treat breast cancer. The antibody-drug conjugate (ADC) targets epidermal growth factor receptor...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >